10-K: Semnur Pharmaceuticals Faces Financial Hurdles, Advances SP-102

Semnur Pharmaceuticals, a late-stage biopharmaceutical company, reported significant losses and a going concern doubt, while advancing its lead non-opioid pain candidate, SP-102, into a second Phase 3 trial.

Summary

• Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on non-opioid pain management products.
• The company's lead product candidate, SP-102 (dexamethasone sodium phosphate viscous gel), is being developed for moderate to severe LRP (sciatica) and has Fast Track designation from the FDA.
• A pivotal Phase 3 CLEAR-1 study completed in March 2022 met primary and secondary endpoints, showing decreased pain intensity for over a month and statistically significant improvement in disability.
• The FDA, in November 2023, requested a confirmatory trial (CLEAR-2) for SP-102 due to risks associated with interventional procedures and the absence of existing FDA-approved epidural steroid products for sciatica.
• The Phase 3 CLEAR-2 trial, designed with FDA guidance for a larger safety database and confirmatory efficacy through repeat injections, initiated in September 2025 and is expected to complete by 2027.
• The company aims for a 505(b)(2) NDA submission after CLEAR-2 completion and a targeted commercial launch of SP-102 in 2028, if approved.
• Semnur reported a net loss of $160.4 million for the year ended December 31, 2025, compared to $4.7 million in 2024, and an accumulated deficit of $275.8 million.
• Cash and cash equivalents were $20 thousand as of December 31, 2025, with $5.9 million cash used in operations during 2025.
• The company is dependent on its parent, Scilex Holding Company, for services and funding, and expects to incur approximately $21.0 million in operating expenses, including $10.0 million for clinical work, over the next twelve months.
• Two significant capital raises, a PIPE SPA for $20.0 million and a Bitcoin SPA for $100.0 million, had not closed as of December 31, 2025, with non-breaching parties having termination options.
• Promissory notes totaling $3.5 million are due in less than a year, and a long-term related party loan of $11.9 million is due to Scilex.
• The company's securities were suspended from trading on Nasdaq on April 16, 2025, and began trading on the OTCQB marketplace on April 17, 2025.
• Semnur is exploring various financing alternatives, including new credit facilities, non-dilutive options (collaborations, debt, royalty financings), and equity financing.
• The company adopted ASU 2023-08 for cryptocurrency accounting effective January 1, 2025, which will require fair value measurement and recognition of gains/losses in net income, potentially increasing financial volatility.
• An Insider Trading Policy and Clawback Policy were adopted, effective September 22, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant financial losses, critical liquidity issues, and the auditor's going concern doubt. While the lead product SP-102 shows promise and is advancing, the FDA's request for an additional Phase 3 trial and the failure of two major capital raises to close by year-end present substantial hurdles and uncertainty for the company's future.

Positives

• SP-102 has Fast Track designation from the FDA, potentially expediting development and review.
• The pivotal Phase 3 CLEAR-1 study achieved primary and secondary endpoints, demonstrating statistically significant and clinically meaningful pain reduction and improved disability in sciatica patients.
• SP-102, if approved, could be the first FDA-approved epidural steroid product for sciatica, offering a first-to-market advantage.
• The product is formulated without neurotoxic preservatives, surfactants, suspensions, or particulates, potentially improving tolerability and safety compared to off-label alternatives.
• The company plans to leverage Scilex's robust commercial infrastructure and experienced sales force for SP-102's commercialization, which has successfully launched three non-opioid pain products.
• SP-102 benefits from a substantial intellectual property portfolio with patents expiring in 2036, creating potential barriers to entry for competitors.
• Management team has extensive experience in the biopharmaceutical industry, including product development and commercialization.
• Preclinical studies showed SP-102 did not result in neurological complications when introduced into blood vessels and demonstrated extended residence time and tolerability.

Negatives

• The company has incurred significant losses since inception, with a net loss of $160.4 million in 2025 and an accumulated deficit of $275.8 million.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and dependence on external financing.
• The FDA requested a confirmatory Phase 3 CLEAR-2 trial for SP-102, delaying the NDA submission and potential commercial launch.
• Two significant capital raise agreements (PIPE SPA for $20.0 million and Bitcoin SPA for $100.0 million) had not closed as of December 31, 2025, and the non-breaching party has an option to terminate.
• The company has only one product candidate, SP-102, and no products approved for commercial sale, making it highly dependent on its success.
• Historical financial statements may not be indicative of standalone operations due to reliance on Scilex for services and funding.
• Certain directors and officers have overlapping positions with Scilex, creating potential conflicts of interest.
• The company's securities were suspended from trading on Nasdaq and now trade on the OTCQB marketplace, indicating a potential loss of market visibility and liquidity.
• The company has promissory notes totaling $3.5 million due in less than a year, and did not make certain scheduled installment payments in Q4 2025, though no default notice was received.

Risks

• Incurring continued significant losses for the foreseeable future and potentially never achieving profitability.
• Inability to obtain additional funding on acceptable terms, or at all, which could lead to reducing or ceasing operations.
• Dependence on a sole or single source supplier and manufacturer for SP-102 and its raw materials, with risks of disruption or non-compliance with FDA regulations.
• Reliance on third parties to conduct clinical trials, with risks of failure to carry out duties, comply with regulations, or meet deadlines.
• Delays in clinical trials leading to increased costs and delayed regulatory approval and revenue generation.
• Inability to obtain regulatory approval for product candidates, or approval for a narrower indication than sought.
• Difficulty in enrolling or maintaining patients in clinical trials, which could cause delays or termination.
• Market opportunities for product candidates being smaller than estimated or approvals based on narrower patient populations.
• Significant competition from pharmaceutical, biotechnology, and specialty pharmaceutical companies with greater resources.
• Failure to attain significant market acceptance of product candidates by physicians, patients, and healthcare payers.
• Uncertainty regarding third-party payor coverage and adequate reimbursement for approved products.
• Results of preclinical studies and early clinical trials not being predictive of future clinical trial results, or not guaranteeing regulatory approval.
• Interim top-line and preliminary data from clinical trials changing as more patient data become available or being subject to audit and verification.
• Product candidates causing undesirable side effects that could delay or prevent regulatory approval.
• Manufacturing complexities and potential problems leading to delays, supply limitations, or harm to business.
• Inability to retain key executives, delaying development efforts and harming business.
• Inability to effectively manage company growth, imposing strain on management and resources.
• Product liability lawsuits leading to substantial liabilities or limitations on commercialization.
• Disruption in research and development facilities due to natural or man-made disasters.
• Inability to maintain patent protection or if the scope of protection is not sufficiently broad, leading to reduced competitiveness.
• Intellectual property rights being invalidated or circumvented, adversely affecting business.
• Confidentiality agreements with employees not adequately preventing disclosure of trade secrets and proprietary information.
• Claims challenging inventorship or ownership of patents and other intellectual property.
• Claims of intellectual property infringement by third parties leading to costly litigation or prevention from selling products.
• Inability to protect intellectual property rights throughout the world, especially in countries with less favorable patent laws.
• Failure to obtain patent term extension and data exclusivity for product candidates.
• Changes in patent laws or jurisprudence diminishing the value of patents.
• Non-compliance with procedural, document submission, and fee payment requirements for patent maintenance.
• Regulatory approval processes being lengthy, time-consuming, and unpredictable, with no guarantee of approval.
• FDA not concluding that SP-102 satisfies Section 505(b)(2) pathway requirements, leading to longer, costlier, and riskier approval.
• Approved product candidates being subject to ongoing and continued regulatory requirements, resulting in significant expense and commercialization limitations.
• Fast track designation not necessarily leading to faster development or approval.
• Changes in funding for the FDA hindering its ability to review and approve products.
• Failure to comply with health and data protection laws and regulations, leading to enforcement actions, penalties, or adverse publicity.
• Business involving hazardous materials and compliance with environmental laws and regulations being expensive and restrictive.
• Misconduct or improper activities by employees, independent contractors, consultants, commercial partners, and vendors.
• Exposure to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws.
• FDA and other regulatory agencies actively enforcing laws prohibiting off-label promotion.
• Healthcare reform measures hindering or preventing commercial success.
• Inability to obtain prior FDA authorization for proposed product brand names.
• Non-compliance with the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, export control laws, and customs laws.
• FDA and comparable foreign regulatory authorities not accepting data from clinical trials conducted outside the U.S.
• Unstable market and economic conditions adversely affecting business, financial condition, and results of operations.
• Volatility in Bitcoin price impacting the company's operating results and share price due to its cryptocurrency treasury strategy.
• The cryptocurrency treasury strategy not being implemented or tested, and potential for unsuccessful outcomes.
• Digital assets being classified as securities, leading to extensive regulation, significant costs, or forced cessation of operations.
• Emergence or growth of other digital assets negatively impacting the price of cryptocurrencies held.
• Lack of legal recourse and insurance for digital assets increasing the risk of total loss in case of theft or destruction.
• Irreversibility of digital asset transactions exposing the company to risks of theft, loss, and human error.
• Changes in accounting treatment of cryptocurrency holdings increasing volatility of financial results.
• Custodially-held cryptocurrencies becoming part of custodians' insolvency estates in bankruptcy, leading to potential loss.
• The Warrants potentially never being in the money and expiring worthless, or their terms being amended adversely.
• The company redeeming unexpired Warrants prior to exercise at a disadvantageous time for holders.
• Future sales, or perception of future sales, of substantial shares causing stock price decline and dilution.
• Operating results fluctuating significantly due to various factors.
• Cash and cash equivalents being adversely affected if financial institutions fail.
• Lack of research or adverse opinions from securities analysts causing stock price and trading volume decline.
• Raising additional capital causing dilution, restricting operations, or requiring relinquishment of product rights.
• Principal stockholders, directors, and executive officers owning a significant percentage of capital stock, influencing management.
• Limitations on the ability to use net operating loss and tax credit carryforwards due to ownership changes.
• Estimates or judgments relating to critical accounting policies proving incorrect, affecting operating results and stock price.
• Anti-takeover provisions in the Charter and Bylaws making acquisitions more difficult.
• Designation of Delaware courts as exclusive forum for certain litigation, limiting stockholders' ability to choose a favorable forum.
• Reduced reporting requirements as an emerging growth company making common stock less attractive to investors.
• Increased costs and management time devoted to compliance as a public company.

Future Outlook

The company anticipates completing the Phase 3 CLEAR-2 trial for SP-102 by 2027 and submitting a 505(b)(2) NDA to the FDA for approval. If approved, the targeted commercial launch of SP-102 is in 2028. The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances SP-102 and expands its corporate infrastructure. Future liquidity will depend on securing additional financing through equity offerings, debt financings, collaborations, or other strategic transactions, as current cash is insufficient for the next 12 months of operations.

Management Comments

• "Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer non-opioid pain management solutions."
• "Through rigorous research and development, we believe we are on the cusp of establishing Semnur as the preeminent name in commercial non-opioid pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies."
• "We believe that we have made substantial progress in demonstrating the rapid onset and enhanced tolerability of our product candidate."
• "Based on the results of this study, we believed that we had sufficient data to support the safety and efficacy of SP-102, which would provide us with a pathway for a 505(b)(2) new drug application (NDA) submission."
• "Given our experience from conducting the Phase 3 CLEAR-1 study, we expect to be able to complete the trial by 2027 and submit our 505(b)(2) NDA to the FDA for approval."
• "If approved, and given SP-102s fast-track designation, this would position us to achieve our targeted commercial launch of SP-102 in 2028."
• "We anticipate that our current supply of sodium hyaluronate will be sufficient to satisfy our clinical and commercial supply requirements for sodium hyaluronate for at least 12 months following our expected commercial launch of SP-102 in 2028."
• "Although we believe such plans, if executed and coupled with the above described sources of liquidity, should provide us with financing to meet our needs, successful completion of such plans is dependent on factors outside of our control."

Industry Context

StockSavvy.ai notes that Semnur Pharmaceuticals operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically targeting the non-opioid pain management market. The focus on non-opioid therapies aligns with broader industry trends and public health initiatives aimed at reducing opioid dependence. The market for epidural steroid injections (ESIs) is substantial, with over 12 million procedures annually in the U.S., but currently lacks an FDA-approved product for sciatica, presenting a significant unmet need that SP-102 aims to address. The company's strategy to leverage the 505(b)(2) regulatory pathway is common for products that build upon existing approved compounds, potentially accelerating development compared to a full NDA. However, the FDA's request for a confirmatory Phase 3 trial for SP-102 highlights the stringent regulatory environment for interventional procedures, even with Fast Track designation. The company's reliance on its parent, Scilex, for commercial infrastructure and R&D support is a common model for smaller biotechs, but also introduces related-party risks and questions about standalone operational capabilities.

Comparison to Industry Standards

• SP-102's Phase 3 CLEAR-1 trial results, with a mean NPRS pain reduction of -1.81 units for SP-102 versus -1.29 for placebo (p=0.002) and an ODI reduction of -8.88 points (p=0.015), are compared to a minimal clinically important difference of -8 for ODI, suggesting clinical meaningfulness.
• The group mean difference (ITT: 0.52; mITT: 1.08) and standardized effect sizes (ITT: 0.28; mITT: 0.68) for CLEAR-1 are noted to be similar to or greater than those of other clinically meaningful analgesics for chronic low back pain (median group mean difference: 0.7 points; SES: 0.32) and off-label ESIs (median group mean difference: 0.49; SES: 0.29).
• SP-102's expected clinical benefit lasting up to approximately 100 days is anticipated to be longer than generic dexamethasone formulations, which pain specialists believe last for a short period.
• Unlike currently used off-label particulate steroid formulations (e.g., methylprednisolone acetate, triamcinolone acetonide, betamethasone sodium phosphate/acetate) that carry FDA class warnings for serious neurologic complications (paraplegia, stroke, paralysis, death), SP-102 is formulated without neurotoxic preservatives, surfactants, suspensions, or particulates, aiming for improved tolerability and safety.
• The projected annual sales of SP-102 in sciatica of $1.5 billion to $2.0 billion by the 5th year of launch, with a maximum market share of approximately 33% of the U.S. ESI market, are based on Syneos Health's analogue assessment of other similar products and primary market research, positioning it as a potential market leader if approved.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any legal proceedings that would individually or in the aggregate have a material adverse effect on its business, financial condition, and results of operations.

Related Party Transactions

• The company is dependent upon Scilex Holding Company (its parent) and its affiliates to provide services and funding to support operations.
• A long-term related party loan of $11.9 million is due to Scilex as of December 31, 2025.
• The Debt Exchange Agreement, effective immediately prior to the Business Combination, converted $54.2 million of outstanding indebtedness between the company and Scilex into 5,423,606 shares of Series A Preferred Stock and 542,361 shares of Common Stock.
• The Transition Services Agreement, entered into with Scilex on September 22, 2025, allows the company to utilize Scilex employees and service providers for finance, HR, IT, legal, R&D support, and commercialization support for three years on a cost-plus 10% basis, with service fees not exceeding $2.0 million per annum until the Scilex-Oramed Note is paid.
• As of December 31, 2025, $0.3 million of service fees were accrued under the Transition Services Agreement, included in the related party loan.
• Scilex (together with certain subsidiaries) controls approximately 81.9% of the voting power of the company (excluding Series A Preferred Stock), giving it significant influence over corporate decisions.
• Certain directors and officers (Jaisim Shah, Henry Ji, Stephen Ma, Jay Chun, Dorman Followwill, Annu Navani, Yue Alexander Wu) hold positions with both Semnur and Scilex, creating potential conflicts of interest.
• Scilex, as the holder of Series A Preferred Stock, has preferential rights, including a liquidation preference and certain voting rights over corporate actions.
• The Scilex Stockholder Agreement grants Scilex the right to designate all directors to the Board and prohibits the company from taking certain actions without Scilex's consent.
• The company's principal executive office is leased from Scilex at no cost until September 2027.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity offerings and potential adverse impact on stock price due to financial losses, going concern doubt, and delays in product commercialization. Scilex's controlling interest and preferential rights of Series A Preferred Stock may limit the influence and returns for public shareholders. The volatility of Bitcoin, if the Biconomy SPA closes, could also impact shareholder value.
• **Employees:** The company plans to increase full-time employees to build its own infrastructure, potentially creating new job opportunities. However, the company's financial instability and dependence on Scilex's support could create job insecurity. The adoption of an Insider Trading Policy and Clawback Policy impacts employee conduct and compensation.
• **Customers (Patients & Healthcare Providers):** Potential for a novel non-opioid treatment (SP-102) for sciatica, addressing an unmet medical need and offering a safer alternative to off-label treatments. Delays in regulatory approval mean patients will wait longer for this potential therapy. Healthcare providers may benefit from an FDA-approved ESI, but reimbursement uncertainty could affect adoption.
• **Suppliers & Manufacturers:** Continued reliance on third-party manufacturers like Lifecore Biomedical for SP-102, providing ongoing business. However, the termination of the Genzyme supply agreement for sodium hyaluronate requires identifying new suppliers, which could impact supply chain stability.
• **Creditors:** Promissory note holders face risks due to the company's financial losses and going concern doubt, although acceleration clauses exist for new financing. The related party loan to Scilex is a significant liability.

Next Steps

• Complete the Phase 3 CLEAR-2 trial for SP-102 by 2027.
• Submit a 505(b)(2) New Drug Application (NDA) to the FDA for SP-102 approval.
• Achieve targeted commercial launch of SP-102 in 2028, if approved.
• Secure additional financing through equity offerings, debt financings, collaborations, government contracts, or other strategic transactions.
• Identify and certify new suppliers for sodium hyaluronate, an excipient for SP-102, following the termination of the Genzyme supply agreement.
• Commence preparation work for the mass production of SP-102 upon completion of the Phase 3 CLEAR-2 trial.
• Initiate negotiations with national insurance companies, Medicare, and Medicaid to secure inclusion of SP-102 in their programs upon FDA approval.
• Enter into a distribution agreement with a major third-party logistic provider for warehousing and distribution of SP-102.
• Increase the number of full-time employees to strengthen research and development, general administrative, manufacturing, regulatory, and commercial functions during the transition period from Scilex.
• Address the outstanding promissory note payments, including those not made in Q4 2025, by March 2026.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by a substantial net loss of $160.4 million in 2025, a cumulative deficit of $275.8 million, and critically low cash reserves of $20 thousand. The independent auditor has raised 'substantial doubt' about its ability to continue as a going concern. Furthermore, two significant capital raises totaling $120 million, crucial for funding operations and clinical trials, had not closed by year-end and face termination risk. While the lead product SP-102 shows promise, the FDA's requirement for an additional Phase 3 trial significantly delays its path to market and increases development costs. The company's reliance on its parent, Scilex, for funding and services, coupled with potential conflicts of interest and Scilex's controlling stake, adds further uncertainty. Given the severe liquidity issues, ongoing losses, regulatory delays, and unconfirmed financing, the stock carries extremely high risk and is likely to experience significant downward pressure.

Keywords

Semnur Pharmaceuticals, SP-102, Sciatica, Non-opioid pain management, Biopharmaceutical, FDA approval, Clinical trials, Phase 3, CLEAR-1, CLEAR-2, SEC filing, 10-K, Financial losses, Going concern, Capital raise, Bitcoin, Cryptocurrency treasury, Intellectual property, Scilex Holding Company, Corporate governance, Risk factors, Biotech investment, Drug development, Regulatory pathway, 505(b)(2) NDA